Two Sigma Advisers LP lifted its stake in LifePoint Health (NASDAQ:LPNT) by 19.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,808 shares of the company’s stock after purchasing an additional 8,600 shares during the period. Two Sigma Advisers LP owned 0.13% of LifePoint Health worth $2,580,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of the company. Stone Ridge Asset Management LLC purchased a new stake in shares of LifePoint Health in the 4th quarter worth $326,000. Guggenheim Capital LLC boosted its holdings in LifePoint Health by 64.6% in the 4th quarter. Guggenheim Capital LLC now owns 103,980 shares of the company’s stock worth $5,178,000 after buying an additional 40,821 shares during the period. Jefferies Group LLC boosted its holdings in LifePoint Health by 115.0% in the 4th quarter. Jefferies Group LLC now owns 8,647 shares of the company’s stock worth $431,000 after buying an additional 4,626 shares during the period. Alliancebernstein L.P. boosted its holdings in LifePoint Health by 1.7% in the 4th quarter. Alliancebernstein L.P. now owns 1,762,076 shares of the company’s stock worth $87,751,000 after buying an additional 28,721 shares during the period. Finally, WINTON GROUP Ltd boosted its holdings in LifePoint Health by 94.4% in the 4th quarter. WINTON GROUP Ltd now owns 204,098 shares of the company’s stock worth $10,164,000 after buying an additional 99,104 shares during the period.
LPNT opened at $47.35 on Friday. LifePoint Health has a 52 week low of $41.45 and a 52 week high of $67.95. The stock has a market cap of $1,847.54, a price-to-earnings ratio of 13.04, a P/E/G ratio of 1.44 and a beta of 0.50. The company has a quick ratio of 1.49, a current ratio of 1.70 and a debt-to-equity ratio of 1.26.
LifePoint Health (NASDAQ:LPNT) last released its quarterly earnings data on Friday, February 23rd. The company reported $0.77 EPS for the quarter, missing the consensus estimate of $0.81 by ($0.04). LifePoint Health had a net margin of 1.46% and a return on equity of 6.34%. The company had revenue of $1.49 billion for the quarter, compared to the consensus estimate of $1.58 billion. During the same period last year, the company earned $1.07 EPS. The firm’s revenue for the quarter was down 7.2% on a year-over-year basis. sell-side analysts forecast that LifePoint Health will post 4.23 EPS for the current fiscal year.
In other LifePoint Health news, insider David M. Dill sold 45,000 shares of the stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $48.52, for a total transaction of $2,183,400.00. Following the completion of the transaction, the insider now owns 252,673 shares of the company’s stock, valued at approximately $12,259,693.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman William F. Carpenter III acquired 21,368 shares of the company’s stock in a transaction on Wednesday, February 28th. The shares were bought at an average cost of $46.80 per share, with a total value of $1,000,022.40. Following the acquisition, the chairman now directly owns 482,668 shares in the company, valued at $22,588,862.40. The disclosure for this purchase can be found here. 8.76% of the stock is owned by corporate insiders.
Several research analysts recently weighed in on LPNT shares. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $50.00 target price on shares of LifePoint Health in a report on Friday, February 23rd. Mizuho reaffirmed a “hold” rating and issued a $51.00 target price on shares of LifePoint Health in a report on Thursday, March 22nd. Wolfe Research raised shares of LifePoint Health from an “underperform” rating to a “peer perform” rating in a report on Friday, March 16th. SunTrust Banks dropped their target price on shares of LifePoint Health to $44.00 and set a “hold” rating for the company in a report on Monday, February 26th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $46.00 target price (down previously from $50.00) on shares of LifePoint Health in a report on Monday, February 26th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $54.31.
WARNING: This news story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/07/two-sigma-advisers-lp-has-2-58-million-stake-in-lifepoint-health-lpnt.html.
LifePoint Health Profile
LifePoint Health, Inc, through its subsidiaries, owns and operates community hospitals, regional health systems, physician practices, outpatient centers, and post-acute facilities in the United States. Its hospitals provide a range of medical and surgical services, such as general surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic care, coronary care, rehabilitation, and pediatric, as well as specialized services, including open-heart surgery, skilled nursing, psychiatric care, and neuro-surgery.
Receive News & Ratings for LifePoint Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifePoint Health and related companies with MarketBeat.com's FREE daily email newsletter.